You are here: Industry Insights > KRAS G12C

News List

Fierce Competition of R&D of KRAS G12C Inhibitors PharmaSources/Yi
January 13, 2022
Recently, the class 1 new drug "ZG19018 Tablets" of Suzhou Zelgen Biopharmaceuticals Co., Ltd. is approved for clinical use in China and the indications are: advanced malignant solid tumors with KRAS G12C mutation.
With the transaction exceeding 300 million US dollars reached, how is the exploration of Chinese inhibitor KRAS G12C? PharmaSources/Yefenghong
September 14, 2021
On September 2, Innovent announced that it had reached a global exclusive licensing agreement with Genfleet. Innovent, as an exclusive partner of Genfleet, will obtain the right to develop and commercialize GFH925...
GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor prnasia
October 13, 2021
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, and Innovent Biologics (HKEX: 01801), a world-class biopharmaceutical company...
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor prnasia
August 03, 2021
Jacobio Pharmaceuticals today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 in China.
Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer prnasia
June 25, 2021
InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today one study in collaboration with Ruijin Hospital, Shanghai Jiaotong University School ...
FDA Approves Lumakras (sotorasib) for KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer drugs
May 31, 2021
AMGN today announced that the U.S. Food and Drug Administration (FDA) has approved Lumakras (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy fda.gov
May 31, 2021
Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one
FDA Grants Sotorasib Priority Review Designation for Advanced, Metastatic NSCLC americanpharmaceuticalreview
February 19, 2021
Amgen announced the U.S. Food and Drug Administration (FDA) has granted Priority Review for sotorasib for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) ...
Amgen Submits Sotorasib Marketing Authorization Application to EMA americanpharmaceuticalreview
December 28, 2020
Amgen announced submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for sotorasib, an investigational KRASG12C inhibitor, for the treatment of adult patients with previously treated KRAS G12C-mutated ...